Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
about
Simultaneous Detection of Hepatitis C Virus (HCV) Core Antigen and Anti-HCV Antibodies Improves the Early Detection of HCV InfectionEvaluation of Hepatitis C Virus Core Antigen Assays in Detecting Recombinant Viral Antigens of Various GenotypesAnalytical Performance Characteristics and Clinical Utility of a Novel Assay for Total Hepatitis C Virus Core Antigen QuantificationAcute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening.Feasibility and cost-benefit of implementing pooled screening for HCVAg in small blood bank settings.Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections.Dynamics of HCV RNA levels during acute hepatitis C virus infection.The mantra of blood safety: time for a new tune?Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assaysSensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samplesRisk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.Seronegative hepatitis C virus infection.Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection.Pathogen safety of human C1 esterase inhibitor concentrate.HCV RNA Testing of Plasma Samples from Cornea Donors: Suitability of Plasma Samples Stored at 4 °C for up to 8 Days.Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors.SARS coronavirus detection methods.Diagnostic Performance of an Immunoassay for Simultaneous Detection of Hcv Core Antigen and Antibodies among Haemodialysis Patients.Estimating window period blood donations for human immunodeficiency virus Type 1, hepatitis C virus, and hepatitis B virus by nucleic acid amplification testing in Southern Pakistan.The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays.Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response.Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland.Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors.Dynamics of viremia in early hepatitis C virus infection.Development, validation and evaluation of a homogenous one-step reverse transcriptase-initiated PCR assay with competitive internal control for the detection of hepatitis C virus RNA.Role of nucleic acid testing in cadaver organ donor screening: detection of hepatitis C virus RNA in seropositive and seronegative donors.Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection.Accuracy of hepatitis C virus core antigen testing in pools among seroconverters.Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.Antibodies to a novel antigen in acute hepatitis C virus infections.First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: a comparative study with various assays.Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.HCV NAT in Austria.A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.Nucleic acid testing for virus screening in Polish blood donors.
P2860
Q27471998-634E5A9B-460A-4035-9405-58FF7276BA1BQ27490457-25A71CDC-4328-49F0-9DFA-68DF5A25FF59Q27491329-87F539F6-F306-4B22-B1FB-76A87DAF6E05Q31050666-B6D11CCE-CE42-4C03-8812-A0FEA0C411D6Q33450364-F9F147A3-53E0-4E1D-BDDC-4FB47E108710Q33629597-63D47D72-6910-4CF4-BB32-36CF3143280FQ34588996-CB497C62-633F-40F5-BC09-0953D0920303Q34771346-E4F28A59-848E-4FFC-BA43-63BCCDB0E345Q35675880-AB494673-E544-4492-9E64-87C785B4FD93Q36022842-6EB82E16-B7AF-43DB-BC09-444A4CC66D18Q36554189-3C8CB818-6C20-4437-90AE-8A84689C3491Q37630304-94FFE6D0-6BEE-4F6D-A924-D9CDA36EFA27Q37631608-9D9D186E-CFB4-435D-90B7-EAC71C91E129Q37692611-4210092D-CE80-49D2-9F6D-8ED90D87AD7EQ37961619-CB1B2E5B-4980-4D69-8A23-96648BD22281Q38421534-FE99465D-190A-45A6-8A5E-F3A093123449Q38992041-30C63EE6-3979-4D1A-9797-F31672F933FAQ39380695-1EC23B02-973F-4BB0-B678-31D3C26C4A37Q40301095-67ED0D50-8C69-4861-8FC8-F359842FA0D5Q40656078-6535A5B2-A1C4-4FC8-B15C-46F477ED67A0Q42132641-F696CFF2-40CE-4CBC-A51A-E7FC783E06D8Q42235935-406F2E55-6409-4472-8920-D17B6B8D4CA8Q42245717-57BB0EA3-61F1-45C6-9286-93C2AD6847B7Q42983576-19ED6306-8501-42C9-B38A-BF939CD68D56Q42987172-2171E767-4EFD-4013-B319-BA62A5D88C3FQ42987806-5F7F8783-0C9D-4B8E-9F05-CC940C88F7A9Q42989340-869A3131-CAE3-41BF-A9B0-214287DBE28DQ42989343-3B107E44-B332-4C12-BCA8-35FD03322F20Q42992916-870502EF-8613-43C9-8116-08589A02723EQ42995600-7A3DB433-43F4-4A75-9746-0DA4E57C51D6Q42996328-068C2CA6-1C25-4EF9-BA9C-D12F300F66ECQ42997213-41BF137A-D9FE-43B8-8880-BCB754951726Q43031733-B4793DE1-5906-448A-A2E9-48E074B3AB8FQ43033135-35D088A3-CB60-4B30-83A6-00C613B94917Q43034612-227CDA16-8D2D-415E-9869-405E658FCA51Q43037357-657B7176-C04B-46F4-8FDD-45188A87E78DQ43047584-A4E988D9-CC1C-4828-8861-7C8760C76F02Q43048509-FC5AD341-1C2C-41C0-880D-FCDFD27FFFCAQ44931522-D6A48E4E-5F78-40F1-82A4-B456572B969DQ45659875-ECCAD9E2-2A74-470A-92D0-CBF0D2DD9035
P2860
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@en
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@nl
type
label
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@en
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@nl
prefLabel
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@en
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@nl
P2093
P2860
P1433
P1476
Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase.
@en
P2093
C Micha Nübling
Gabriele Unger
Johannes Löwer
Michael Chudy
Steven Raia
P2860
P304
P356
10.1046/J.1537-2995.2002.00166.X
P577
2002-08-01T00:00:00Z